Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Amygdala Neurosciences.

    Client Virtual Booth

    AMYGDALA NEUROSCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Amygdala Neurosciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    509 Hale St. Palo Alto, CA 94301 USA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.amygns.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder

    Details:

    The financing aims to fund the clinical development of the company-lead product ANS-858, which is investigating in the early-stage clinical trial for the treatment of patients with alcohol use disorder.


    Lead Product(s): ANS-858

    Therapeutic Area: Psychiatry/Psychology Product Name: ANS-858

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: ABMRF

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Financing May 14, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Amygdala Neurosciences Awarded $2.0 Million NIH Grant to Conduct IND Enabling Studies

    Details:

    The funding will support the IND-enabling and early-stage development of selective, reversible, orally bioavailable ALDH2 inhibitor ANS-858 to treat alcohol use disorder.


    Lead Product(s): ANS-858

    Therapeutic Area: Psychiatry/Psychology Product Name: ANS-858

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: National Institute on Alcohol Abuse and Alcoholism

    Deal Size: $2.0 million Upfront Cash: Undisclosed

    Deal Type: Funding August 01, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    farmak-a-s-m-2024-08-26

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search